Guidelines on the treatment with integrated traditional Chinese medicine and western medicine for severe coronavirus disease 2019. (December 2021)

• Record Type: Journal Article
• Authors: Li, Zhi-Yu; Xie, Zhi-Jun; Li, Hai-Chang; Wang, Jian-Jian; Wen, Xiang-Hui; Wu, Shou-Yuan; Chen, Jiao; Zhang, Juan-Juan; Li, Lin; Guo, Qiang-Qiang; Liu, Qiu-Ping; Lan, Hui; Jiang, Yue-Peng; Li, Dian-Ming; Xu, Xiao-Feng; Song, Si-Yue; Zhang, Ming; Fang, Shan; Lai, Wei-Dong; Gao, Yi-Ni; Zhang, Feng-Qi; Luo, Wen-Qing; Lou, Yu; Chen, Wu; Zhang, Xia-Feng; Wang, Ke-Er; Zhou, Ming-Qian; He, Yuan-Fang; Xi, An-Ran; Gao, Yan; Zhang, Yi; Chen, Yao-Long; Wen, Cheng-Ping;
• Is Part Of: Pharmacological research. Volume 174(2021)
• Publication Date: 2021-12
• Subjects: AGREE Appraisal of Guidelines for Research and Evaluation -- AMSTAR Assessing the Methodological Quality of Systematic Reviews -- BFJP Bufei Jianpi -- COVID-19 Coronavirus Disease 2019 -- CPMs Chinese patent medicines -- EEG the evidence evaluation group -- FHN femoral head necrosis -- GDG the guideline development group -- GRADE Grades of recommendations, assessment, development, and evaluation -- HCQ hydroxychloroquine -- HFNC high flow nasal cannula -- HSBD Huashi Baidu -- HXZQ Huoxiang Zhengqi -- IMV invasive mechanical ventilation -- IOM Institute of Medicine -- IVIg intravenous immunoglobulin -- JHQG Jinhua Qinggan -- LHQW Lianhua Qingwen -- Lpv/R lopinavir/ritonavir -- MERS Middle East Respiratory Syndrome -- NHCPRC National Health Commission of the People's Republic of China -- NIV non-invasive ventilation -- PICO participants, intervention, comparison, outcome -- PHEIC Public Health Emergency of International Concern -- QFPD Qingfei Paidu -- RCT Randomized control trial -- RIGHT Reporting Items for Practice Guidelines in Healthcare -- SARS Severe Acute Respiratory Syndrome -- TCM traditional Chinese medicines -- TCZ tocilizumab -- UC usual care -- WHO World Health Organization -- XBJ Xuebijing -- XFBD Xuanfei Baidu -- YQYY Yiqi Yangyin -- YYQR Yangyin Qingre; Guideline -- COVID-19 -- Traditional Chinese medicine -- Integrated Chinese and western medicine; Pharmacology -- Periodicals; Pharmacology -- Periodicals; Research -- Periodicals; Médicaments -- Recherche -- Périodiques; Pharmacologie -- Périodiques; 615.105
• DOI: 10.1016/j.phrs.2021.105955
• Languages: English
• ISSNs: 1043-6618

Abstract

Abstract: Severe Coronavirus Disease 2019 (COVID-19) is characterized by numerous complications, complex disease, and high mortality, making its treatment a top priority in the treatment of COVID-19. Integrated traditional Chinese medicine (TCM) and western medicine played an important role in the prevention, treatment, and rehabilitation of COVID-19 during the epidemic. However, currently there are no evidence-based guidelines for the integrated treatment of severe COVID-19 with TCM and western medicine. Therefore, it is important to develop an evidence-based guideline on the treatment of severe COVID-19 with integrated TCM and western medicine, in order to provide clinical guidance and decision basis for healthcare professionals, public health personnel, and scientific researchers involved in the diagnosis, treatment, and care of COVID-19 patients. We developed and completed the guideline by referring to the standardization process of the "WHO handbook for guideline development", the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system, and the Reporting Items for Practice Guidelines in Healthcare (RIGHT). Graphical Abstract: ga1